Yesterday, after providing an update on the overall survival (OS) data on its previously disclosed advanced breast cancer patients, BCTX have been sharply increased from $3.20 to an incredible $6.18, digging deeper, the motives of investors are clear and their hopes for this company are becoming more real.
Considering owning shares of this company – it seems to be a perfect time, but does it worth it from a long-term perspective? Looking back, throughout the last year, today’s company achieved its peak! Experts consider the fact is that the experiment conducted over the past 12 months turned out to be a trump card in the company’s sleeve, thereby blowing up the market according to a successful report.
For potential investors, this appears to be the best time to purchase shares, with hopes of further promotion of the company’s medicines and an increase in commodity turnover. The company deserves special attention, since in most cases such breakthroughs in medicine lead to success, given that the company will come to a successful implementation.